Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Femasys Inc. SEC filings document the company’s women’s health medical-device business, Nasdaq-listed common stock, operating results, and product-related corporate updates. Recent 8-K filings furnish quarterly and annual financial results and disclose material events tied to executive appointments, employment agreements, financing instruments, and listing compliance matters.
Proxy materials cover annual and special stockholder meetings, board elections and governance matters, reverse stock split authorization, and share-issuance approvals linked to capital-structure provisions. Other filings describe senior secured convertible notes, warrant amendments, Nasdaq minimum bid price compliance, and the company’s emerging growth company reporting status.
Femasys Inc. filed an 8-K to share an updated corporate presentation outlining its women’s reproductive health portfolio and growth strategy. The slide deck highlights FDA-cleared and internationally approved products, including FemaSeed for in-office fertility treatment and FemBloc, a non-surgical permanent birth control now in a U.S. pivotal trial.
The company emphasizes a large unmet fertility and contraception market, noting record-low U.S. fertility rates and limited innovation in first-line care. It presents clinical data showing FemaSeed achieved about double the pregnancy rate of intrauterine insemination in a trial, and early FemBloc data showing a 0% pregnancy rate versus historical surgical controls, along with favorable in-office economics for OB/GYN practices.
Femasys Inc. reported net income of $846,100 for the quarter ended March 31, 2026, compared with a net loss a year earlier. Sales rose to $424,889, driven mainly by FemVue, while operating expenses were $4,489,816, reflecting higher sales and marketing but sharply lower research and development spending.
The company’s profit was primarily due to $5,069,633 of other income, including large non‑cash gains from changes in the fair value of its convertible note conversion option and warrant liabilities. Cash and cash equivalents fell to $5,386,041 after $4,143,508 of cash used in operating activities, and the accumulated deficit reached $144,980,044.
Management states that existing cash, expected product revenue and current facilities are only sufficient to fund operations into the third quarter of 2026, and that substantial doubt exists about Femasys’ ability to continue as a going concern without additional financing. The company highlights significant potential dilution from outstanding convertible notes and multiple warrant series as it pursues commercialization of its women’s health portfolio and the pivotal FemBloc trial.
Femasys Inc. reported financial results for the quarter ended March 31, 2026 and provided a corporate update. Sales were $424,889, up from $341,264 a year earlier, while loss from operations narrowed to $4,223,533 from $5,460,607.
Benefiting from fair value adjustments to its conversion option and warrant liabilities, the company recorded net income of $846,100, versus a prior-year net loss of $5,896,839. Cash and cash equivalents were $5,386,041 as of March 31, 2026, and management believes current cash resources can fund operations into the third quarter of 2026.
Commercially, Femasys is accelerating rollout of FemaSeed intratubal insemination with its FemSperm product family, enabling in-office fertility care. Clinically, it has initiated patient enrollment in the FINALE pivotal trial for FemBloc non-surgical permanent birth control, a key step toward potential U.S. FDA approval.
Femasys Inc. will hold its 2026 Annual Meeting of Stockholders on June 24, 2026 at 9:00 a.m. Eastern in Suwanee, Georgia. Stockholders of record at the close of business on April 27, 2026 may vote.
Investors are asked to elect two Class II directors, Charles Larsen and Kenneth Eichenbaum, to three-year terms and to ratify KPMG LLP as independent auditor for the year ending December 31, 2026. The proxy describes board independence, committee structure, director compensation, major stockholders, executive pay and employment agreements, a Dodd-Frank–compliant clawback policy, and procedures for submitting proposals for the 2027 annual meeting.
Femasys Inc. held a Special Meeting where stockholders approved two key measures. First, they authorized the board to implement a reverse stock split of the common stock at any ratio between 1-for-2 and 1-for-25 at any time before May 1, 2027, giving the board flexibility to reduce the number of shares outstanding. Second, they approved, for Nasdaq rule purposes, issuing more than 19.99% of the company’s common stock upon conversion of senior secured convertible notes and exercise of multiple warrant series if anti-dilution or price adjustments push conversion or exercise prices below the Nasdaq Minimum Price.
Femasys Inc. is asking stockholders at an April 29, 2026 special meeting to approve three key proposals affecting its capital structure and Nasdaq listing status.
First, the company seeks authority to implement a reverse stock split of its common stock at any ratio between 1-for-2 and 1-for-25 any time before May 1, 2027. The main goal is to lift the share price above Nasdaq’s $1.00 Minimum Bid Price Requirement and avoid potential delisting, while also creating more authorized but unissued shares for possible future financings.
Second, Femasys requests approval under Nasdaq Listing Rules 5635(c) and 5635(d) to issue additional common shares upon conversion of senior secured convertible notes and the exercise of multiple series of warrants if anti-dilution or price adjustments reduce conversion or exercise prices below the Nasdaq Minimum Price. This could meaningfully dilute existing holders but is tied to capital raised in a November 2025 private placement and a March 2026 amendment.
Third, the board seeks authority to adjourn the meeting to solicit more proxies if there are not enough votes to pass the reverse split or issuance proposals.
FEMASYS INC reported that Chief Operating Officer John Charles Canning received a grant of stock options as part of his compensation. The award covers 150,000 options to purchase common stock at an exercise price of $0.38 per share, expiring on March 30, 2036.
The options vest in equal annual installments over four years, beginning on March 30, 2027, and each vesting installment requires that he remain employed by the company or one of its subsidiaries on the applicable vesting date.
Femasys Inc Chief Operating Officer John Charles Canning filed an initial Form 3 showing his beneficial ownership in the company. He reported holding 30,000 shares of Femasys common stock, owned directly. The filing records his position but does not report any recent share purchases or sales.
Femasys Inc. appointed John Canning as Chief Operating Officer, effective March 30, 2026, and entered into an employment agreement outlining his compensation and equity incentives. He brings more than 25 years of medical device leadership experience from Terumo Aortic, Bolton Medical, and Medtronic.
Mr. Canning will receive a $450,000 annual base salary and a target annual bonus equal to 40% of base salary. As a material inducement to join Femasys under Nasdaq Listing Rule 5635(c)(4), he was granted a nonstatutory option to purchase 150,000 shares, vesting over four years, with the exercise price set at the Nasdaq closing price on the March 30, 2026 grant date. If terminated without cause or he resigns for good reason, he is entitled to nine months of salary continuation, unpaid prior-year bonus, and subsidized COBRA premiums, subject to a release of claims.